Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)

Inclusion Criteria: * 18 years or older * Primary pigmented or amelanotic choroidal melanoma measuring 16 mm or less in the largest basal diameter and 6 mm or less in the apical height. * Location of the tumor, posterior to the equator of the eye. * Documented growth of tumor by A-B scan. * Ability to provide written informed consent and comply with the study assessment for the full duration of the study. Exclusion Criteria: * Pregnancy or lactation. * Premenopausal women not using adequate contraception. * Current infection or inflammation in either eye. * Extension of tumor into the orbit. * Regional spread or metastatic disease. * Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated. * Any known allergy to any of the components to be used in the study. * Participation in another simultaneous medical investigation or trial.